168 related articles for article (PubMed ID: 20698138)
1. Cervix cancer screening in Croatia within the European Cervical Cancer Prevention Week.
Skopljanac-Macina L; Mahovlić V; Ovanin-Rakić A; Barisić A; Rajhvajn S; Juric D; Babić D; Corusić A; Oresković S
Coll Antropol; 2010 Jun; 34(2):613-7. PubMed ID: 20698138
[TBL] [Abstract][Full Text] [Related]
2. Pap test--with or without vaginal smear?
Milicić-Juhas V; Perić M; Pajtler M; Prvulović I; Curzik D
Coll Antropol; 2010 Mar; 34(1):69-74. PubMed ID: 20437636
[TBL] [Abstract][Full Text] [Related]
3. Cervical cancer screening programme in Primorsko-Goranska County, Croatia--the results of the pilot study.
Vrdoljak-Mozetic D; Ostojić DV; Stemberger-Papić S; Janković S; Glibotić-Kresina H; Brncić-Fischer A; Benić-Salamon K
Coll Antropol; 2010 Mar; 34(1):225-32. PubMed ID: 20437641
[TBL] [Abstract][Full Text] [Related]
4. History of the use of HPV testing in cervical screening and in the management of abnormal cervical screening results.
Cox JT
J Clin Virol; 2009 Jul; 45 Suppl 1():S3-S12. PubMed ID: 19651367
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of visual inspection with acetic acid (VIA), Lugol's iodine (VILI), cervical cytology and HPV testing as cervical screening tools in Latin America. This report refers to partial results from the LAMS (Latin AMerican Screening) study.
Sarian LO; Derchain SF; Naud P; Roteli-Martins C; Longatto-Filho A; Tatti S; Branca M; Erzen M; Serpa-Hammes L; Matos J; Gontijo R; Bragança JF; Lima TP; Maeda MY; Lörincz A; Dores GB; Costa S; Syrjänen S; Syrjänen K
J Med Screen; 2005; 12(3):142-9. PubMed ID: 16156945
[TBL] [Abstract][Full Text] [Related]
6. High-grade cervical abnormalities and screening intervals in New South Wales, Australia.
Schindeler S; Morrell S; Zuo Y; Baker D
J Med Screen; 2008; 15(1):36-43. PubMed ID: 18416954
[TBL] [Abstract][Full Text] [Related]
7. European guidelines for quality assurance in cervical cancer screening: recommendations for clinical management of abnormal cervical cytology, part 1.
Jordan J; Arbyn M; Martin-Hirsch P; Schenck U; Baldauf JJ; Da Silva D; Anttila A; Nieminen P; Prendiville W
Cytopathology; 2008 Dec; 19(6):342-54. PubMed ID: 19040546
[TBL] [Abstract][Full Text] [Related]
8. Cytological screening for cervical cancer in the province of Limburg, Belgium.
Arbyn M; Van Nieuwenhuyse A; Bogers J; De Jonge E; De Beeck LO; Matheï C; Buntinx F
Eur J Cancer Prev; 2011 Jan; 20(1):18-24. PubMed ID: 20805755
[TBL] [Abstract][Full Text] [Related]
9. Early detection of precursors of cervical cancer with cervical cytology and visual inspection of cervix with acetic Acid.
Dhaubhadel P; Vaidya A; Choudhary P
JNMA J Nepal Med Assoc; 2008; 47(170):71-6. PubMed ID: 18709035
[TBL] [Abstract][Full Text] [Related]
10. Screening for cervical disease in mature women: strategies for improvement.
Colgan TJ; Clarke A; Hakh N; Seidenfeld A
Cancer; 2002 Aug; 96(4):195-203. PubMed ID: 12209660
[TBL] [Abstract][Full Text] [Related]
11. A study of Pap test history and histologically determined cervical cancer in NSW women, 1997-2003.
Morrell S; Taylor R; Wain G
J Med Screen; 2005; 12(4):190-6. PubMed ID: 16417696
[TBL] [Abstract][Full Text] [Related]
12. [Role of cytological test for cervices to identify human papillomavirus in the screening program on serious cervical lesion].
Wang GP; Li RZ; Wu LN; Li J; Liu ZH; Wang C; Zhou YQ; Weng LM; Wu RF
Zhonghua Liu Xing Bing Xue Za Zhi; 2009 Jun; 30(6):626-30. PubMed ID: 19957634
[TBL] [Abstract][Full Text] [Related]
13. Risk factors for cervical neoplasia in Denmark.
Kjaer SK
APMIS Suppl; 1998; 80():1-41. PubMed ID: 9693662
[TBL] [Abstract][Full Text] [Related]
14. Comparison of HPV test versus conventional and automation-assisted Pap screening as potential screening tools for preventing cervical cancer.
Nieminen P; Vuorma S; Viikki M; Hakama M; Anttila A
BJOG; 2004 Aug; 111(8):842-8. PubMed ID: 15270934
[TBL] [Abstract][Full Text] [Related]
15. [Organized cervical cancer screening for underpriviledged women].
Piana L; Leandri FX; Jacqueme B; Heid P; Corti J; Andrac-Meyer L; Sancho-Garnier H
Bull Cancer; 2007 May; 94(5):461-7. PubMed ID: 17535784
[TBL] [Abstract][Full Text] [Related]
16. Expression of the MN antigen in cervical papanicolaou smears is an early diagnostic biomarker of cervical dysplasia.
Liao SY; Stanbridge EJ
Cancer Epidemiol Biomarkers Prev; 1996 Jul; 5(7):549-57. PubMed ID: 8827360
[TBL] [Abstract][Full Text] [Related]
17. Effect of an antepartum Pap smear on the coverage of a cervical cancer screening programme: a population-based prospective study.
Nygård M; Daltveit AK; Thoresen SO; Nygård JF
BMC Health Serv Res; 2007 Jan; 7():10. PubMed ID: 17244348
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of atypical glandular cells on Pap smears: experience from a region with a high incidence of cervical cancer.
Sawangsang P; Sae-Teng C; Suprasert P; Srisomboon J; Khunamornpong S; Kietpeerakool C
J Obstet Gynaecol Res; 2011 Jun; 37(6):496-500. PubMed ID: 21159042
[TBL] [Abstract][Full Text] [Related]
19. An audit of the cervical cancer screening histories of 246 women with carcinoma.
Duggan MA; Nation J
J Low Genit Tract Dis; 2012 Jul; 16(3):263-70. PubMed ID: 22297213
[TBL] [Abstract][Full Text] [Related]
20. A 1-year experience with liquid-based and conventional papanicolaou smear in Thammasat University Hospital.
Suwannarurk K; Bhamarapravatana K; Thaweekul Y; Mairaing K; Poomtavorn Y; Pattaraarchachai J
J Med Assoc Thai; 2011 Dec; 94 Suppl 7():S47-51. PubMed ID: 22619906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
